A Multi-Center Phase II Study to Compare MER-101 [zoledronic acid] (20mg) Tablets To Intravenous Zometa [zoledronic acid] 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients.

Trial Profile

A Multi-Center Phase II Study to Compare MER-101 [zoledronic acid] (20mg) Tablets To Intravenous Zometa [zoledronic acid] 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs Zoledronic acid (Primary) ; Zoledronic acid
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Merrion Pharmaceuticals
  • Most Recent Events

    • 15 May 2009 Comprehensive results are expected to be presented at ASCO in late May 2009, according to a Merrion media release.
    • 15 May 2009 Preliminary results were presented at 7th International Cancer conference in May 2009, according to a Merrion media release.
    • 19 Feb 2009 End date added from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top